Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05315700 · ClinicalTrials.gov registry record · Phase 1

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

A Phase 1 study of Solid Tumors, sponsored by ORIC Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
350
Enrollment target
20
Study locations

NCT05315700: Recruiting Phase 1 study of Solid Tumors, sponsored by ORIC Pharmaceuticals.

NCT05315700 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by ORIC Pharmaceuticals. The registered enrollment target is 350 participants, above the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05315700, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by ORIC Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
350 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Primary Outcome

RP2D as determined by interval 3+3 dose escalation design

Conditions Studied

Solid Tumors

Interventions

  • DRUG ORIC-114
  • DRUG Chemotherapy drug

Study Locations (20)

California

  • City of Hope - Duarte
  • City of Hope - Huntington Beach
  • City of Hope - Irvine
  • City of Hope - Long Beach
  • University of California, San Francisco - San Francisco

Other

  • Chris O'Brien Lifehouse - Camperdown
  • Peter MacCallum Cancer Centre - Melbourne
  • One Clinical Research, Hollywood Medical Centre - Nedlands

Florida

  • Mayo Clinic - Jacksonville
  • Moffitt Cancer Center - Tampa

Connecticut

  • Yale Cancer Center - New Haven

District of Columbia

  • Georgetown University - Washington D.C.

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2022-03-10
Est. Completion 2027-09
Phase Phase 1
ORIC Pharmaceuticals

7 total trials

What NCT05315700 shows while recruiting

NCT05315700 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target (24% higher).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which ORIC-114 is the first listed.

NCT05315700 names 20 study sites across 13 states, led by California, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT05315700 about?

NCT05315700 is a clinical study titled "Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration". The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advance...

What is the current status of trial NCT05315700?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2022-03-10. Estimated completion is 2027-09.

What conditions does trial NCT05315700 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT05315700?

The interventions under investigation include: ORIC-114 (DRUG), Chemotherapy drug (DRUG).

Who is sponsoring clinical trial NCT05315700?

This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05315700 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05315700's enrollment target sits among peer trials

350 15th of 125 higher than 111 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05315700

Source: ClinicalTrials.gov NCT05315700, the US trial registry maintained by the National Library of Medicine. NCT05315700 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.